No single vali date d outcome measure encompassed all potential patient benefits from using a CGS .
A variety of different domains were identified , including anxiety and depression , coping , decision-making , distress , family environment , health status , knowledge , mood , perception of risk , perceived personal control , psychological impact , quality of life , satisfaction and expectations , self-esteem , spiritual well-being , and worry .
Some important aspects of patient benefit from CGS are not covered by existing outcome measures .
OBJECTIVE This systematic review aim ed to inform research ers and policymakers about what vali date d outcome measures are available to evaluate clinical genetics services ( CGS ) and the need for new measures .
Randomized trial of a specialist genetic assessment service for familial breast cancer.
BACKGROUND Because of the growing dem and for genetic assessment , there is an urgent need for information about what services are appropriate for women with a family history of breast cancer . Our purpose was to compare the psychologic impact and costs of a multidisciplinary genetic and surgical assessment service with those of current service provisions . METHODS We carried out a prospect i ve r and omized trial of surgical consultation with ( the trial group ) and without ( the control group ) genetic assessment in 1000 women with a family history of breast cancer . All P : values are from two-sided tests . RESULTS Although statistically significantly greater improvement in knowledge about breast cancer was found in the trial group ( P : = .05 ) , differences between groups in other psychologic outcomes were not statistically significant . Women in both groups experienced statistically significant reductions in anxiety and found attending the clinics to be highly satisfying . An initial specialist genetic assessment  cost pound 14.27 ( U.S. $ 22.55 ) more than a consultation with a breast surgeon . Counseling and genetic testing of affected relatives , plus subsequent testing of family members of affected relatives identified as mutation carriers , raised the total extra direct and indirect costs per woman in the trial group to pound 60.98 ( U.S. $ 96.35 ) over costs for the control subjects . CONCLUSIONS There may be little benefit in providing specialist genetics services to all women with a family history of breast cancer . Further investigation of factors that may mediate the impact of genetic assessment is in progress and may reveal subgroups of women who would benefit from specialist genetics services
No single vali date d outcome measure encompassed all potential patient benefits from using a CGS .
A variety of different domains were identified , including anxiety and depression , coping , decision-making , distress , family environment , health status , knowledge , mood , perception of risk , perceived personal control , psychological impact , quality of life , satisfaction and expectations , self-esteem , spiritual well-being , and worry .
Some important aspects of patient benefit from CGS are not covered by existing outcome measures .
OBJECTIVE This systematic review aim ed to inform research ers and policymakers about what vali date d outcome measures are available to evaluate clinical genetics services ( CGS ) and the need for new measures .